EYPT vs. TXG, TRNS, ALNT, LAB, SENS, CTKB, QSI, AEHR, QTRX, and MASS
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Allient (ALNT), Standard BioTools (LAB), Senseonics (SENS), Cytek Biosciences (CTKB), Quantum-Si (QSI), Aehr Test Systems (AEHR), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
EyePoint Pharmaceuticals vs.
10x Genomics (NASDAQ:TXG) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
10x Genomics has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.
10x Genomics currently has a consensus price target of $15.81, suggesting a potential upside of 85.54%. EyePoint Pharmaceuticals has a consensus price target of $25.38, suggesting a potential upside of 350.71%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe EyePoint Pharmaceuticals is more favorable than 10x Genomics.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 4.7% of EyePoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, EyePoint Pharmaceuticals had 4 more articles in the media than 10x Genomics. MarketBeat recorded 14 mentions for EyePoint Pharmaceuticals and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.90 beat EyePoint Pharmaceuticals' score of 0.82 indicating that 10x Genomics is being referred to more favorably in the media.
EyePoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
10x Genomics has a net margin of -29.90% compared to EyePoint Pharmaceuticals' net margin of -226.57%. 10x Genomics' return on equity of -25.40% beat EyePoint Pharmaceuticals' return on equity.
EyePoint Pharmaceuticals received 404 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 70.36% of users gave EyePoint Pharmaceuticals an outperform vote while only 50.77% of users gave 10x Genomics an outperform vote.
Summary
EyePoint Pharmaceuticals beats 10x Genomics on 10 of the 18 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy EYPT Stock Free EYPT Stock Alerts